Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 417

1.

Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

Kwong LM.

Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6. Review.

2.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

3.

Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.

Levitan B, Yuan Z, Turpie AG, Friedman RJ, Homering M, Berlin JA, Berkowitz SD, Weinstein RB, DiBattiste PM.

Vasc Health Risk Manag. 2014 Mar 26;10:157-67. doi: 10.2147/VHRM.S54714. eCollection 2014.

4.

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.

PMID:
22023098
5.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
6.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

7.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.

Thromb Haemost. 2010 Oct;104(4):760-70. doi: 10.1160/TH10-01-0071. Epub 2010 Aug 30. Review.

PMID:
20806107
8.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
9.

Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.

Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I.

Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):601-15. doi: 10.1586/erp.11.65.

PMID:
21958104
10.

Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.

Friedman RJ, Sengupta N, Lees M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):299-306. doi: 10.1586/erp.11.15. Review.

PMID:
21671699
11.
12.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

13.

An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N.

J Med Econ. 2011;14(2):238-44. doi: 10.3111/13696998.2011.564699. Epub 2011 Mar 9.

PMID:
21385145
14.

A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.

Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W.

Postgrad Med. 2013 Jul;125(4):141-53. doi: 10.3810/pgm.2013.07.2686.

PMID:
23933902
15.
17.

Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.

Ageno W.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):569-76. doi: 10.1586/erc.09.37.

PMID:
19505271
18.
19.
20.

[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].

Gómez Arrayas I, Suárez Fernández C, Gómez Cerezo JF, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Salud Publica. 2012 Dec;86(6):601-12. doi: 10.4321/S1135-57272012000600006. Spanish.

Supplemental Content

Support Center